SCHEMBL29796129

SCHEMBL29796129

OCCOCCOCCOCCSSc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.47
EHMT1 Q9H9B1 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 4/20 0.36
MAPT P10636 1/20 0.36
HDAC1 Q13547 4/20 0.36
HDAC2 Q92769 4/20 0.36
MEN1 O00255 3/20 0.36
LMNA P02545 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15140934 1.00 EHMT2 (0.47) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL31290207 1.00 EHMT2 (0.47) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL18369713 1.00 EHMT2 (0.47) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL30833293 0.98 EHMT2 (0.48) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL14984823 0.98 EHMT2 (0.48) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL10326593 0.92 EHMT2 (0.55) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL11821480 0.91 EHMT2 (0.57) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL4532065 0.89 HDAC1 (0.42) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL12575508 0.86 ALDH1A1 (0.40) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL31456218 0.85 EHMT2 (0.47) EHMT2EHMT1APOBEC3GALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034226-A1 GLYCOTARGETING THERAPEUTICS ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2026-02-05 US disclosed
EP-4031173-A1 COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE Anokion SA (CH) 2022-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034226-A1 GLYCOTARGETING THERAPEUTICS LGALS1, ST6GAL1, LGALS2 EHMT2 2396/4885EHMT1 2008/4885APOBEC3G 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.